
Kate Walsh Talks About Multi-Cancer Early Detection Testing
Grey's Anatomy star Kate Walsh called this decision a 'no brainer' in both a serious and punny way. It's her decision to team up with the company GRAIL to advocate for more multi-cancer early detection testing in a campaign they're calling 'Generation Possible.'
Now MCED, short for multi-cancer early detection, isn't exactly a term that's already bandied about regularly like 'OMG' or 'IYKYK.' It's a newer term that may at first sound quite technical. But breaking the term down to its component parts can help understand what it is. 'Cancer" along with 'early detection' means trying to catch cancer in its early stages before it's spread and becomes much more difficult to treat. 'Testing' implies some kind of test to do this.
And "multi-cancer' means a test that can look for multiple different cancers at a time. This is in contrast to tests like mammography, colonoscopy or prostate specific antigen blood levels that look for cancer in just very specific parts of the body. You wouldn't, for example, use colonoscopy to look for lung cancer, unless you somehow weren't paying attention and inserted the scope in a very wrong place.
Walsh is serious about the early detection of cancer in large part because of what happened to her parents. Her father was diagnosed with late stage lung cancer. 'It was not detected early enough and he succumbed unfortunately to cancer a year and a half later, quite young." Walsh recalled. "He was just three days short of his 61st birthday.' That was over three decades ago when Walsh herself was only 23.
Her mother had a different experience with cancer. 'My mother survived breast cancer,' Walsh recalled in a recent conversation. 'She was diagnosed at 62, but they caught it early enough to where she had double mastectomy where she was able to live cancer-free for another 30 years. We were very fortunate.' Walsh also mentioned a good friend from high school who died of breast cancer.
Here's the punny part. GRAIL now has a multicancer detection test that's commercially available. Walsh explained, 'This technology has never been available before, it was not there in my parents' generation,' hence the name of the campaign Generation Possible. 'It was a no brainer to work with GRAIL,' Walsh added. 'I should say pun not intended since I did have a brain tumor, which was very fortunately not cancerous, ten years ago.'
Yes, Walsh had her own cancer scare in 2015, when Walsh was in her mid-40s. The first symptoms that came to a head, so to speak, were rather subtle. 'I was just exhausted and then I got more and more tired.' Her Pilates trainer then noticed that her right side was dipping. Not in a 'hip dip' Pilates move type of way. But in a what's-going-on type of way.
It took a while for her to act on these various symptoms, which she attributed to 'American can-do and stoicism. I'm sure it's just, you know, tired. Or I just did a big TV show, I burned myself out. I was working out really hard I burned myself out.'
But eventually after 'all these little subtle markers" got 'more and more pronounced,' she got an MRI of your brain. 'And then lo and behold I had a pretty sizable tumor in there," Walsh recounted. "So, three days later I was in surgery and had it had it out and thankfully they were able to get all of it and it was benign.'
It turned out to be a meningioma. A meningioma is a non-cancerous overgrowth of the meninges, the tissues that wrap around the brain sort of like Saran Wrap around a tomato. Except that one's brain is a bit more important than a tomato.
Kate Walsh starred as Dr. Addison Shephard in ABC TV's medical drama series "Grey's Anatomy." Here ... More she is pictured with Ellen Pompeo, who played Dr. Meredith Grey, and Patrick Dempsey, who played Dr. Derek Shepherd. (Photo by Craig Sjodin/Disney General Entertainment Content via Getty Images)
In general, waiting for symptoms to appear before getting checked for cancer is not a good proposition. It's a bit like waiting for your house to fall into pieces before doing something about a termite infestation. Cancer is when some cells in your body start to grow abnormally in an uncontrolled manner. If you catch these calls early enough, you may be able to pluck them out or kill them before they spread anywhere else. In these early stages, though, many cancers don't cause any symptoms. Symptoms really start emerging after the cancer has spread, which, in turn, can significantly decrease the chances of successful treatment. It can be much tougher to get each and every cancer cell out of your body.
On top of that, people can delay going to the doctor. After all, the words 'I have a doctor's appointment' aren't typically followed by a 'Woooo.' Even Walsh, who played Dr. Addison Montgomery in the TV series Grey's Anatomy and Private Practice, has had a very common reluctance to see doctors. 'For someone who played a doctor on TV for the better part of a decade and back and forth over the years, I never really liked going to the doctor,' Walsh said. 'I really did the bare minimum."
After her mother was diagnosed with breast cancer, Walsh did start advocating for people to get cancer screenings such as mammograms. 'But I still get nervous and intimidated [during doctor's appointments],' Walsh related. 'I always say to people, bring your husband or wife or a partner or a friend to ask questions that you might forget to ask or take notes, because I think it's anxiety provoking, you know? It's not a friend to friend conversation. There's an awe about doctors.'
When you don't go to the doctor regularly or are like a deer in headlights during the appointment, you may not end up getting screened for cancer properly. Currently, the American Cancer Society recommends the following:
In addition, you can get screened for skin cancer with the doctor searching your body for suspicious looking stuff.
If you notice, though, that's only a small fraction of the over 200 possible cancers that people could possibly get. For most other cancers, there historically has not been ways to detect them early.
The Galleri test is now commercially available. GRAIL is seeking FDA approval of the test. (Photo: ... More Courtesy of GRAIL)
That's prompted researchers to try to find some sort of detectable signal that is present across different cancers at their early stages. It's helpful to find something that is common in many different cancers because you want the screening to be as practical as possible. It could get a little daunting if a doctor were to say, 'OK, get ready for the over 100 different scopes to be inserted into different parts of your body.' It's also good to have tests as painless as possible. Because who wants more pain in life.
All of these motivations have given rise to the MCED concept. GRAIL has been advocating for MCED because, naturally, they have a commercially available test aiming to do the MCED thing. GRAIL's Galleri test looks in blood samples for DNA fragments with certain methylation patterns suggestive of cancer. The test is based on the fact that all cells in your body, healthy or otherwise, shed their DNA to varying degrees. That can leave various fragments of DNA circulating through your bloodstream.
These DNA fragments can be methylated to varying degrees. Methylation is when a methyl group consisting of carbon and hydrogen atoms gets attached to the DNA molecules in your cells. A cell uses such methylation to turn on and off sections of its DNA, in turn, changing what proteins the DNA codes for at the time.
Josh Ofman, MD, MSHS, is president at GRAIL, chronicled how the concept behind the Galleri test arose by accident: 'It really dated back to 2015 at Ilumina. The origin story was they did a big study with about 125,000 pregnant women.' The study was part of Illumina's testing of their non-invasive prenatal test that entailed checking pregnant mothers for genomic abnormalities. 'There were 10 cases where the DNA just looked really abnormal,' said Ofman. 'The medical director at that time was a guy named Rick Klausner, who was the ex head of the National Cancer Institute, and he said you only see the abnormal DNA like this in cancer." Ofman continued with, "They called those 10 women back and all 10 of them had an asymptomatic cancer. And that's when the light bulbs went off in Illumina.' Illumina subsequently spun out GRAIL to develop the technology that could test for DNA fragments with methylation patterns that are indicative of cancer.
That eventually led to the Galleri test that was launched as a commercial product in 2021. A big test of the test conducted from the end of 2019 through 2020 was the PATHFINDER study, a prospective cohort study of 6,662 folks 50 years of age and above who didn't have at the time symptoms suggestive of cancer. Results from PATHFINDER as described in a GRAIL press release alongside a publication in The Lancet in 2023 found the test to be 97% accurate in detecting cancer.
Now, commercially available doesn't necessarily mean readily financially available to everyone. While you or your employer can currently pay for the test if either of you have the cash to shell out, insurance typically won't cover it yet. Ofman said that they are in the process of trying to get FDA approval of Galleri, 'Where we hope to become the first multi early detection test that has an FDA approval.'
Of course, GRAIL isn't the only place working on MCED stuff. Other scientists around the world are trying to find different ways to catch more cancers earlier and more efficiently with less invasiveness. There is a big need for such things as cancer is one of the leading causes of death around the world, accounting for nearly one in six of all deaths, according to the World Health Organization. And the rates of cancers like prostate cancer continue to rise, especially among younger people.
Therefore, it is a 'no brainer' to want more ways to detect more different cancers earlier as Kate Walsh does. It is also a 'no brainer' to ensure that more people get access to cancer screening technology. With further scientific research—assuming that science gets the proper amount of support and funding—and more support of screening tests, all of these things may become increasingly possible for the current generations and beyond.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Genentech and Roche Present New Insights in Alzheimer's Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC
– Trontinemab's Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining <5% – – Design of the Phase III TRONTIER 1 and 2 studies of trontinemab in early symptomatic Alzheimer's disease featured, with initiation planned in 2025 – – Plans for new Phase III trial investigating trontinemab in preclinical Alzheimer's disease, in people at high risk of cognitive decline – – New real-world data support Elecsys pTau217 as a standalone blood test, comparable to a PET scan, for rule-in and rule-out identification of amyloid pathology – SOUTH SAN FRANCISCO, Calif., July 28, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer's development portfolio is being presented at the Alzheimer's Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer's across the entire patient journey. Featured oral presentations include the latest results from the ongoing Phase Ib/IIa Brainshuttle™ AD study, which continue to support rapid and robust reduction of amyloid plaques, and design of the Phase III TRONTIER 1 and 2 studies of investigational trontinemab for early symptomatic Alzheimer's disease, with initiation planned later this year. As part of its growing Alzheimer's development program, Roche announced today its plans for an additional Phase III trial to investigate trontinemab in preclinical Alzheimer's disease. The trial will focus on individuals at risk of cognitive decline, with the goal of potentially delaying or preventing the progression of the disease to symptomatic stages. "Alzheimer's disease represents one of the greatest challenges in healthcare today and tackling it requires early detection and effective therapeutics," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "Trontinemab is designed to target a key driver of Alzheimer's disease biology more effectively in the brain. Combining new treatment avenues with advanced diagnostics may enable earlier and potentially more effective intervention. With plans for Phase III trials in both early symptomatic and preclinical Alzheimer's disease, we are advancing science with the goal of delaying—and ultimately preventing—progression of this devastating condition." Late-breaking oral and poster presentations highlight the potential of Roche's Elecsys® pTau217 as a reliable and accessible blood-based biomarker test, providing comparable results to PET scan and cerebrospinal fluid (CSF) diagnostics for rule-in and rule-out diagnosis of amyloid pathology, a hallmark of Alzheimer's disease, across care settings. The test, which received Breakthrough Device Designation from the U.S. Food and Drug Administration last year, will also be utilized in Roche's TRONTIER studies. "Blood based testing for Alzheimer's disease has the potential to greatly improve patient access and decrease the time to definitive disease diagnosis," said Matt Sause, CEO of Roche Diagnostics. "Our data show that the Elecsys pTau217 test performs comparably to PET scans but can be performed with a simple blood draw and analyzed in a routine clinical laboratory. This has the potential to transform the diagnosis of Alzheimer's and provide clear answers to caregivers, patients, and their families." Up to 75% of people living with symptoms of Alzheimer's disease globally have not been diagnosed, and those who have, waited an average of 2.8 years, and even less have received any form of treatment. Diagnostics play a crucial role in addressing the global challenge of Alzheimer's, not only to detect and identify people with the disease early, even before the first symptoms, but also to rule out those who may or may not benefit from specific treatments. Pharmaceuticals In a 90-minute Featured Research session, designs were shared for the Phase III studies, TRONTIER 1 and 2, which will initiate later this year, investigating the efficacy and safety of investigational trontinemab in people with early Alzheimer's disease. The primary endpoint will measure the change in cognition and function based on the Clinical Dementia Rating – Sum of Boxes scale after 18 months of treatment. Secondary endpoints will include assessments of cognition, function, behavioral symptoms, and quality of life. A pre-screening study, TRAVELLER, based on a brief clinical assessment and a plasma biomarker, which will be identified using the Elecsys pTau217 test, has also been initiated, to enable broader community outreach and extend access to these trials to more diverse populations representative of Alzheimer's disease. New data on the latest results for trontinemab from the completed dose-expansion part of the 1.8 mg/kg and 3.6 mg/kg cohorts from the ongoing Phase Ib/IIa Brainshuttle AD study continued to show rapid and robust reduction of amyloid plaques in the brain as measured by amyloid positron emission tomography (PET). In the 3.6 mg/kg cohort, trontinemab reduced amyloid levels below the 24 centiloid positivity threshold in 91% of participants (n=49/54) after 28 weeks of treatment; 72% (n=39/54) achieved deep clearance below 11 centiloids. These data were reinforced by early and significant reductions in fluid biomarkers of Alzheimer's disease, including total tau, phosphorylated Tau (pTau)181, pTau217, and neurogranin measured in CSF and continues to show a favourable safety and tolerability profile. Amyloid-related imaging abnormalities-edema/effusion (ARIA-E) continued to be observed in <5% of participants (blinded data; N=4/149 across 1.8 and 3.6 mg/kg dose cohorts). All cases were radiographically mild, one was associated with mild and transient symptoms. Diagnostics Roche will present data on a new study comparing the pTau217/Ab42 plasma ratio to the high-throughput, fully automated Elecsys pTau217 assay. The presentation will report on the accuracy of these tools in detecting amyloid pathology. Together with the high throughput and full automation of the assay, these data will assess the potential of Elecsys pTau217 as an accurate standalone rule-in and rule-out test that could be scaled up for broad implementation in routine clinical practice worldwide. Additionally, results from a cohort-based model of healthcare utilization in the U.S. demonstrated that using the Elecsys® pTau181 blood-based rule-out test in primary care scenarios improved diagnostic accuracy and reduced resource use compared with the current standard-of-care clinical, cognitive and imaging tests. If made available in primary care settings, the Roche Elecsys® pTau181 blood test has the potential to reliably avoid the need for further confirmatory testing in nearly all people who receive a negative result. This will avoid the need for these people to undergo unnecessary testing using CSF or PET, which often come with long wait times and high cost, resulting in further delays to diagnosis and cost to healthcare systems. Medicine Abstract title Presentation number (type) Presentation date (session) Time Abstracts will be available on the AAIC website. Pharmaceuticals Next wave of innovation in Alzheimer's disease therapeutics: The value of novel active transport mechanisms Featured Research Session (FRS), Talk 1 Room 718 27 July 2025, 2pm - 3:30pm EDT Cath Mummery, Roberto Villaseñor, Jens Niewoehner, Scarlett Barker, Luka Kulic Latest results from the dose-expansion part (Part 2) of the Brainshuttle™ AD study of trontinemab in people with Alzheimer's disease Featured Research Session (FRS), Talk 2 Room 718 27 July 2025, 2pm - 3:30pm EDT Luka Kulic, Fabien Alcaraz, Gregory Klein, Stephen Salloway, Carsten Hofmann, João A. Abrantes, Stella Yilmaz, Denise Sickert, Maddalena Marchesi, Jakub Wojtowicz, Andres Schneider, Ruth Croney, David Agnew, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel Interim biomarker results for trontinemab, a novel Brainshuttle™ antibody in development for the treatment of Alzheimer's disease Featured Research Session (FRS), Talk 3 Room 718 27 July 2025, 2pm - 3:30pm EDT Gregory Klein, Gil Rabinovici, Henrik Zetterberg, Matteo Tonietto, Tobias Bittner, Daria Rukina, Fabien Alcaraz, Carsten Hofmann, Maddalena Marchesi, Jakub Wojtowicz, Ruth Croney, David Agnew, João A. Abrantes, Franziska Schaedeli Stark, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel, Luka Kulic TRONTIER 1 and TRONTIER 2: Pivotal trials of trontinemab in early symptomatic Alzheimer's disease Featured Research Session (FRS), Talk 4 Room 718 27 July 2025, 2pm - 3:30pm EDT Janice Smith, Catherine Mummery, Jeffrey L. Cummings, Gil Rabinovici, Stephen Salloway, Reisa Sperling, Henrik Zetterberg, Angeliki Thanasopolou, Christopher Lane, Paul Delmar, Gregory Klein, Ruth Croney, Jakub Wojtowicz, Carsten Hofmann, Luka Kulic, Hideki Garren Diagnostics Evaluating the Impact on Diagnostic Performance and Healthcare Resource Utilization of Introducing a plasma rule-out test in the Alzheimer's Disease Diagnostic Pathway Poster #102729 27 July 2025, 7:30am - 4:15pm EDT Sophie Roth, Gustaf Ortsäter, Joana Amorim Freire Location tbc Evaluating the Clinical Performance of the Elecsys pTau217 Plasma Immunoassay to Detect Amyloid Pathology in a Routine Clinical Practice Cohort Poster #96679 28 July 2025, 7:30am – 4:15pm EDT Sayuri Hortsch, Niels Borlinghaus, Alexander Jethwa, David Caley, Annunziata Di Domenico, Craig Ritchie Clinical performance and effect of pre-analytical variation of plasma pTau217 alone versus the plasma pTau217/Aβ42 ratio for the identification of amyloid pathology Oral Developing Topics #108585 3-23-DEV Developing Topics on Tau Biomarkers 29 July 2025, 2:00pm – 3:30pm EDT Christopher M. Rank, Joana Amorim Freire, Alexander Jethwa, Annunziata Di Domenico, Christina Rabe, Marc Suárez-Calvet, Colin L. Masters, Tobias Bittner Accuracy of cerebrospinal fluid biomarker ratios to determine amyloid positron-emission tomography status: a diagnostic test accuracy meta-analysis Poster #100941 28 July 2025, 7:30am – 4:15pm EDT Pablo Martinez-Lage, Eino Solje, Julian G. Martins, Sraboni Sarkar Equity in diagnosis through adequate clinical trial design in diagnostic performance studies Poster #102804 30 July 2025, 7:30am - 4:15pm EDT Imke Kirste, David Caley, Clara Quijano Rubio, Margherita Carboni Investigating Differences in Patients Enrolled in a Clinical Study Based on Referral Type Poster #108110 30 July 2025, 7:30am - 4:15pm EDT Sophie Roth, Laura Schlieker, Sayuri Hortsch, Joana Amorim Freire, David Caley About trontinemab Trontinemab is an investigational Brainshuttle bispecific 2+1 amyloid-beta targeting monoclonal antibody specifically engineered for enhanced access to the brain to enable rapid reduction of amyloid in people with Alzheimer's disease. Trontinemab is designed for the efficient transport across the blood-brain barrier to target aggregated forms of amyloid beta and remove amyloid plaques in the brain. The uniqueness of trontinemab is based on Roche's proprietary Brainshuttle technology combining an amyloid beta-binding antibody with a transferring receptor (TfR1) shuttle module. As a result, high central nervous system (CNS) exposure of trontinemab may be achieved at low doses, leading to a rapid and deep amyloid clearance. Due to its unique properties, trontinemab might unlock the full potential of disease-modifying monoclonal antibodies by effectively penetrating the brain and potentially leading to slowing of disease progression. About Roche in Alzheimer's Disease With more than two decades of scientific research in Alzheimer's disease, Roche is working towards a day when we can detect and treat the disease early, in order to slow down, stop or even prevent its progression to preserve what makes people who they are. Today, the company's Alzheimer's disease portfolio spans investigational medicines for different targets, types and stages of the disease, including trontinemab. On the diagnostics side, it also includes approved and investigational tools, including digital and blood-based tests and CSF assays, aiming to more effectively detect, diagnose and monitor the disease. Yet the global challenges of Alzheimer's disease go well beyond the capabilities of science, and making a meaningful impact requires collaboration both within the Alzheimer's community and outside of healthcare. Roche will continue to work together with numerous partners with the hope to transform millions of lives. About Genentech in Neuroscience Neuroscience is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases. Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer's disease, Huntington's disease, Parkinson's disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit View source version on Contacts Media Contact: Meghan Hindman (650) 467-6800Advocacy Contact: Jenee Williams (650) 303-2958Investor Contacts: Loren Kalm (650) 225-3217Bruno Eschli +41616875284 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data


Medscape
an hour ago
- Medscape
More Data Cement COVID's Impact on Patients With Cancer
TOPLINE: New data confirm the impact COVID infection can have on patients with cancer and identified several risk factors associated with hospitalization and death. Receipt of chemotherapy as well as a baseline history of stroke, atrial fibrillation, or pulmonary embolism were each associated with nearly double the risk for COVID-related hospitalization. Prior vaccination halved this risk. Older age and earlier hospitalization were associated with a greater risk for death. METHODOLOGY: Patients undergoing active cancer treatment are at increased risk for severe COVID-19 due to immunosuppression, but risk factors for hospitalization and death are not well-defined. Researchers conducted a prospective cohort study involving 1572 patients with cancer (median age, 60 years; 53.4% women), enrolled within 14 days of a positive SARS-CoV-2 test; participants had received active treatment for cancer within 6 weeks before testing or had undergone prior stem cell transplant or CAR T-cell therapy. Patient screening and enrollment took place between May 2020 and February 2022. Treatments included chemotherapy (34.3%), targeted therapy (27.7%), and immunotherapy (10.6%). Breast (23.6%) and lung (13.9%) cancers were the most common cancer types. Overall, 64% of participants had metastatic disease, and at enrollment, 64% had not received a COVID vaccine. Study outcomes were COVID-related hospitalization or death. Risk factors for hospitalization and for death among hospitalized patients were evaluated separately. TAKEAWAY: At 90 days after an initial positive test, COVID-related mortality was 3% and remained stable at subsequent follow-ups. The highest incidence occurred in patients with lymphoma, followed by those with acute leukemia or lung cancer; the lowest incidence occurred in those with other types of solid tumors and blood cancers. Hospitalization for COVID-19 occurred in 18.4% of patients within 90 days of enrollment. The risk for hospitalization was elevated among patients who received chemotherapy (hazard ratio [HR], 1.97) and those with a history of stroke, atrial fibrillation, and pulmonary embolism (HR, 1.78). Vaccination prior to infection reduced the risk for hospitalization by nearly half (HR, 0.52). Hospitalization for COVID-19 within 30 days of infection was associated with an increased risk for death (HR, 14.6). Among patients hospitalized for COVID within 30 days, age 65 years or older was the only significant predictor of COVID-specific death (HR, 3.49). Over the 2-year follow-up, there were 1739 disruptions to cancer treatment; 50.7% of these were attributed to COVID-19, and most occurred within 30 days of a positive test. IN PRACTICE: 'The data from this prospective cohort study confirm and expand previous retrospective case series that have found factors, including hematologic cancers, chemotherapy receipt, and lung cancer, as associated with COVID-19 severity,' the authors of the study wrote, noting that the results 'showed that COVID-19 had a significant impact on patients with cancer, including hospitalization, treatment disruptions, and death.' SOURCE: This study, led by Brian I. Rini, MD, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, was published online in JAMA Oncology. LIMITATIONS: Information on specific strains was not available. This study lacked a control group of patients without COVID-19, which limited causal inference. Additionally, as participants were enrolled through the National Cancer Institute trial networks, generalizability to a broader population could be limited. DISCLOSURES: This study was funded in part by the Coronavirus Aid, Relief, and Economic Security Act and the National Cancer Institute National Clinical Trials Network, Experimental Therapeutics Clinical Trials Network, and Community Oncology Research Program grants via the U10 funding mechanism. Several authors declared receiving grants and/or personal fees and having other ties with various sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
2 hours ago
- Yahoo
MrFluffyFriend Launches XXXXL Calming Dog Bed for Large and Anxious Dogs
Over 600,000 dogs sleep better already — now available in 48 inch (120cm) & 56 inch (140cm) with up to 60% off and free shipping on Image by MrFluffyFriend LOS ANGELES, July 27, 2025 (GLOBE NEWSWIRE) -- MrFluffyFriend, a fast-growing U.S. pet wellness brand known for its calming products, announces the launch of its XXXXL Calming Dog Bed, specially designed for large breeds and dogs prone to anxiety. The oversized beds, now available in 120cm and 140cm, offer unmatched comfort and emotional relief thanks to premium materials and calming features rooted in behavioral science. Made with ultra-soft vegan faux fur, deep orthopedic padding, and a raised rim for added head and neck support, the XXXXL Calming Bed creates a soothing nest-like environment that helps dogs feel safe, supported, and calm — especially during fireworks, thunderstorms, or when left home alone. 'We've helped over 600,000 dogs sleep better with our calming beds,' says a MrFluffyFriend spokesperson. 'Our community asked for something big enough for their Labradors, Golden Retrievers, Huskies — and we listened. This launch is all about showing that big dogs deserve big comfort, too.' According to veterinarians, over 70% of dogs experience anxiety at some point, which can lead to restlessness, whining, and destructive behavior. MrFluffyFriend's calming design mimics a mother's touch, helping to trigger the release of serotonin and reduce stress naturally. Key Features: Sizes: XXXL (48 in / 120 cm) and XXXXL (56 in / 140 cm) Raised rim for orthopedic support and security Ultra-soft faux fur mimics a mother's touch Machine washable cover + water-resistant, non-slip base Hypoallergenic and pet-safe materials Ideal for large breeds and multi-dog households The launch is accompanied by a limited-time offer of up to 60% off, free shipping across the U.S., and a 30-day risk-free trial, making it easier than ever for pet parents to try the product. Early feedback has been overwhelmingly positive, with customers praising the bed's luxurious size, fluffiness, and noticeable calming effect. Some report their dogs sleep longer, bark less, and even retreat to the bed during stressful moments like vet visits or fireworks. About MrFluffyFriend Founded with a mission to help pets feel safe, calm, and loved, MrFluffyFriend is a pet lifestyle brand trusted by dog lovers in over 25 countries. From calming beds to wellness accessories, every product is developed with science-backed design and premium materials to ensure pets thrive — emotionally and physically. Learn more at Media Contact: Thomas, H. info@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data